FDA Approves Moderna's mRNA Flu Vaccine for Adults 50+

The U.S. Food and Drug Administration (FDA) has granted approval for mFlusiva, a novel influenza vaccine developed by Moderna, marking the first use of mRNA technology in a flu shot for adults aged 50 and older. This approval utilizes the same foundational mRNA technology that was instrumental in the development of COVID-19 vaccines. Moderna, a biotechnology company headquartered in Cambridge, Massachusetts, anticipates that mFlusiva will become available at select retail locations in the near future, coinciding with the broader rollout of other flu vaccines for the upcoming fall vaccination season. While existing flu vaccine options are available in the United States, including specific formulations recommended for individuals aged 65 and above, influenza continues to cause tens of thousands of deaths annually, with older adults representing a particularly vulnerable demographic. The annual necessity for flu vaccine updates stems from the virus's tendency to mutate, requiring vaccines to be recalibrated to effectively target circulating strains. Vaccines produced using mRNA technology offer a significant advantage in manufacturing speed compared to traditional vaccine types. This expedited production capability is considered particularly beneficial in scenarios where the influenza virus undergoes rapid or unexpected mutations, potentially necessitating the swift development of new vaccine doses. The FDA's full approval for mFlusiva in individuals aged 50 to 64 is supported by findings from a comprehensive study involving 40,000 participants. This study demonstrated that the new mRNA vaccine reduced the incidence of flu cases by approximately 27% when compared to a routinely administered flu vaccine brand. For the demographic aged 65 and older, the FDA has issued an accelerated approval for mFlusiva. This designation is based on preliminary data from a smaller study that indicated the vaccine elicited a robust immune response relative to an existing high-dose vaccine specifically designed for seniors. The company is currently conducting an additional postmarketing study to further substantiate its efficacy and safety in this age group. Moderna's safety data for mFlusiva indicated no significant adverse events. However, some temporary reactions were observed, including pain at the injection site, fever, headache, fatigue, and general body aches. These reactions occurred at a slightly higher frequency compared to current flu shots. The FDA's decision to approve mFlusiva follows a period of notable public discussion regarding the vaccine earlier in the year, involving a dispute with a then-senior official at the FDA.